Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.59 |
| ▸ | PDE4A | P27815 | 9/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753579 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15580926 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL302947 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869339 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869362 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15580915 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL29679711 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL752748 | 0.94 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16572255 | 0.91 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL706429 | 0.91 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619195-B1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | UNICHEM LAB LTD (IN) | 2025-07-23 | — | — | EP | claimed |
| CN-118851979-A | Preparation method of apremilast | 潍坊市海欣药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-113121404-B | Synthesis method of apremilast | 江苏先声药业有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118047701-A | Preparation method of apremilast intermediate | 浙江华义制药有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-116730900-A | One-pot preparation and solvent recycling method for synthesizing apremilast | 天津力生制药股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-115850129-B | Process for the preparation of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine | 凯莱英生命科学技术(天津)有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115850129-A | Preparation method of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine | 凯莱英生命科学技术(天津)有限公司 | 2023-03-28 | — | — | CN | claimed |
| EP-3341359-B1 | PROCESS FOR PREPARATION OF APREMILAST | GLENMARK LIFE SCIENCES LTD (IN) | 2022-03-23 | — | — | EP | claimed |
| CN-112250533-B | Synthesis method of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine | 中山奕安泰医药科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | claimed |
| WO-2017033206-A2 | SOLID STATE FORMS OF N-[2-[(1 S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-03-02 | — | — | WO | claimed |
| WO-2016174685-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2016-11-03 | — | — | WO | claimed |
| WO-2016146990-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | CIPLA LIMITED (IN) | 2016-09-22 | — | — | WO | claimed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | claimed |
| CN-103864670-B | The preparation method of A Pusite | SUZHOU MINGYUE MEDICAL TECHNOLOGY CO., LTD. (CN) | 2015-08-26 | — | — | CN | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | PDE4B 6/4885PDE4A 1/4885PDE4C 8/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | PDE4B 7/4885PDE4A 3/4885PDE4C 11/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.